Nystatin Indications and ICD-10 Coding for Superficial Candida Skin Infections
Nystatin is indicated for superficial cutaneous candidiasis including intertrigo in skin folds (such as diaper dermatitis), and the appropriate ICD-10 code is B37.2 (Candidiasis of skin and nail). 1, 2
Primary Indications for Nystatin
Nystatin is effective for treating candidal skin infections that occur as intertrigo in skin folds, which are particularly common in the diaper region. 2 The Infectious Diseases Society of America confirms that topical antifungal agents including nystatin, clotrimazole, and miconazole are all equally effective options for cutaneous candidiasis, with no distinction between them for intertrigo or other candidal skin infections. 1
Specific Clinical Scenarios:
- Diaper dermatitis with Candida infection – Apply nystatin cream 3-4 times daily or with each diaper change for 7-14 days until clinical healing is achieved 2, 3
- Intertriginous candidiasis (skin fold infections) – Same dosing regimen as above 1, 2
- Oropharyngeal candidiasis – Nystatin suspension (100,000 U/mL, 4-6 mL 4 times daily) or pastilles (200,000 U each, 1-2 pastilles 4-5 times daily) for 7-14 days, though this carries only moderate-quality evidence compared to clotrimazole 1
ICD-10 Coding
The correct ICD-10 code for superficial Candida skin infection is B37.2 (Candidiasis of skin and nail). This code applies to:
- Candidal intertrigo
- Candidal diaper dermatitis
- Cutaneous candidiasis in any location
Critical Success Factors for Treatment
Keeping the infected area dry is as important as the antifungal therapy itself. 1, 2 This is particularly crucial in skin fold infections where moisture accumulation promotes fungal growth. Failure to maintain dryness can lead to treatment failure even with appropriate antifungal therapy. 2
Treatment Duration and Monitoring:
- Continue treatment for 7-14 days until complete clinical healing – not just symptomatic improvement 2
- Reassess if no improvement after 7 days, as this may indicate treatment failure or misdiagnosis 2
- Discontinuing treatment prematurely after symptomatic improvement but before complete healing can lead to recurrence 2
When Nystatin May Not Be Optimal
Avoid nystatin in the following situations:
- Moderate-to-severe oropharyngeal disease – oral fluconazole (100-200 mg daily) is superior with high-quality evidence 1
- Immunocompromised patients with recurrent infections – systemic therapy preferred due to resistance risk 1
- Esophageal candidiasis – nystatin is ineffective for this indication 1
- Prophylaxis in neutropenic patients – nystatin cannot be recommended as it has been shown ineffective 4
Alternative Topical Options
Clotrimazole and miconazole are equally effective alternatives with the same efficacy profile for cutaneous candidiasis. 1 Clotrimazole may be preferred when:
- Shorter treatment duration is desired for vulvovaginal candidiasis 1
- Broader spectrum coverage is needed (clotrimazole also covers dermatophytes) 1
- Patient has failed or is intolerant to nystatin 1
Common Pitfalls to Avoid
- Treating Candida colonization without symptoms – approximately 10-20% of women normally harbor Candida species, and identifying Candida in the absence of symptoms should not lead to treatment 1
- Using oil-based formulations with latex contraceptives – these can weaken latex condoms and diaphragms 1
- Ignoring underlying predisposing conditions – persistent or recurrent infections may indicate diabetes or immunodeficiency requiring additional evaluation 2